Common Stock, par value $0.007 per share
- Symbol
- BIAF
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
bioAffinity Technologies, Inc.
BIAFNASDAQEQUITYCurrent
Other Events
Item 8.01. Other Events. On October 15, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing that it will sponsor a Learning Theater presentation at CHEST 2026, the annual meeting of the American College of Chest Physicians, on the evolving role of CyPath Lung® in improving lung cancer risk stratification and managing pulmonary nodules in…
Company context
bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung, is a non-invasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
Current securities
Registered securities in this filing
bioAffinity Technologies, Inc. · 8-K · Filed 2026-10-15
Warrants to purchase Common Stock
- Symbol
- BIAFW
- Exchange
- NASDAQ
- Classification
- WARRANT
- Status
- Current
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item
8.01. Other Events.
On
October 15, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing
that it will sponsor a Learning Theater presentation at CHEST 2026, the annual meeting of the American College of Chest Physicians, on
the evolving role of CyPath Lung® in improving lung cancer risk stratification and managing pulmonary nodules in patients at high
risk for lung cancer. The presentation will include discussion of the Company’s positive research data in the development of its
new test measuring asthma and COPD-related lung inflammation and drug-related receptors.
A
copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Filed exhibits (1)
Exhibit 99.1 News Release bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026 Chief Medical Officer Gordon Downie, MD, to host CHEST 2026 Learning Theater on clinical use of CyPath® Lung Presentation to address current challenges in pulmonary nodule management and to discuss preliminary research data from the ongoing development of a new, investigational test for asthma and COPD bioAffinity Technologies’ Medical and Scientific Advisory Board to convene in conjunction with CHEST 2026 SAN ANTONIO, Texas - October 15, 2026 - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, will sponsor a Learning Theater presentation at CHEST 2026, the annual meeting of the American College of Chest Physicians, on the evolving role of CyPath® Lung in improving lung cancer risk stratification and managing pulmonary nodules in patients at high risk for lung cancer. The presentation will include discussion of the Company’s positive research data in the development of its new test measuring asthma and COPD…
Open exhibit ↗